CLINUVEL PHARMACEUTICALS LTD is expanding its VALLAURIX Research, Development & Innovation Centre in Singapore with strategic investment from the Singapore Economic Development Board (EDB). The five-year plan focuses on developing liquid long-acting drug delivery platforms to optimize therapeutic outcomes for patients. The expansion will increase the facility’s capabilities in creating novel pharmaceutical formulations for advanced stage programs, solidifying its position as a global hub for peptide formulations. CLINUVEL’s commitment to Singapore aims to address complex therapeutic challenges and deliver peptide-based medicines through innovative research and development.

Read more at GlobeNewswire: CLINUVEL expands Singapore RD&I Centre to pioneer